Cover Image
市場調查報告書

OpportunityAnalyzer:B細胞型非何傑金氏淋巴瘤 - 市場機會的分析與未來預測

OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018

出版商 GlobalData 商品編碼 311411
出版日期 內容資訊 英文 178 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:B細胞型非何傑金氏淋巴瘤 - 市場機會的分析與未來預測 OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018
出版日期: 2014年08月25日 內容資訊: 英文 178 Pages
簡介

本報告實施B細胞型非何傑金氏淋巴瘤(NHL)治療方法的研發最新動向調查與相關市場的未來預測,並調查及預測疾病概要和現階段的治療方法、未滿足需求與市場機會的評價、今後10年發病件數的預測值、臨床試驗的進行狀況、新治療藥物的產品線評價、今後市場動向等,其結果由下列摘要形式闡述。

第1章 目次

第2章 簡介

第3章 疾病概要

  • 病因與病理
    • 無痛性與攻擊性B細胞型非何傑金氏淋巴瘤(NHL)的病理
  • 症狀

第4章 疾病管理

  • 診斷
    • 診斷上的分類
  • 治療方法概要

第5章 流行病學

  • 疾病的背景情事
  • 風險因子與共病症
  • 全球趨勢
    • 美國
    • 歐洲主要5國(5EU)
  • 預測手法
    • 所使用的情報來源
    • 預測的假設與手法
    • 年齡標準發生率
  • B細胞NHL的流行病學預測(今後11年分)
    • 濾泡性淋巴瘤
    • 周邊區域淋巴瘤
    • 瀰漫性大型B細胞淋巴癌(DLBCL)
    • 被套細胞淋巴瘤
  • 討論
    • 流行病學預測相關結論
    • 分析的限制
    • 分析的強項

第5章 現在的治療選項

  • 概要
  • 產品簡介:主要品牌、濾泡性淋巴瘤的情況
    • Imbruvica(ibrutinib)
    • Revlimid(lenalidomide)
    • Rituxan/MabThera(rituximab)
    • Treanda(bendamustine)
    • Velcade(bortezomib)
    • Zevalin(ibritumomab tiuxetan)
    • Zydelig(idelalisib、GS-1101、CAL-101)

第7章 未滿足需求的評價與機會分析

  • 概要
  • 未滿足需求的分析
    • 為無痛性NHL病患的促進延命與延遲再發的安全且高容許的第一線藥劑
    • 被套細胞淋巴瘤病患的生存率改善
    • 第一線治療後的BLBCL病患的治療率改善
    • 預測與預後診斷的分子生物標記
  • 市場機會分析
    • 更具成本效益的治療方法
    • 濾泡性淋巴瘤病患的強化/維持療法的改善
    • 第一線DLBCL與被套細胞淋巴瘤治療的新藥劑

第8章 研發(R&D)策略

  • 概要
    • 複數的NHL亞型標的設定及各種治療方法以獲取患者佔有率
    • 再發性NHL病患內部的新標的抑制
    • 為替代化學免疫療法體制,開發與Rituxan/MabThera組合形式的新藥劑
    • 透過開發次世代治療方法以取代特許失效時的標準治療方法的企業管理
    • 檢查企業成為贊助商的臨床試驗:為避免臨床試驗最終階段的風險,在初期階段與小型生技企業合作
    • 為改善病患的便利性,開發新藥物傳遞的路徑
  • 臨床試驗設計
    • 無痛性B細胞NHL
    • 攻擊性B細胞NHL
    • 臨床試驗達成度的評價方法
    • 切實的對照藥群(Comparator Arms)

第9章 產品線分析

  • 概要
  • 臨床試驗階段有前景的醫藥品
    • Arzerra(ofatumumab)
    • Gazyva(obinutuzumab)
  • 初期階段的創新方式
    • Adcetris(brentuximab vedotin)
    • Alisertib (MLN8237)
    • Blinatumomab (AMG-101)
    • Copanlisib (BAY 80-6946)
    • Y-90 Epratuzumab
    • 嵌合抗原受體T細胞療法

第10章 產品線評價分析

  • 主要產品線藥劑的臨床面基準
  • 主要產品線藥劑的商業面基準
  • 各企業與產品的競爭力評價
  • 今後5年的營業額預測
    • 美國
    • 歐洲主要5國

第11章 附錄

圖表一覽

目錄

The competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL), currently revolves around multiple rounds of Rituxan-based chemotherapy. Although patients can achieve durable remissions to induction therapy, those patients who relapse after primary treatment have poor prognosis and high unmet needs. Several promising pipeline agents are set to have a dramatic impact on treatment of these relapsed/refractory patients over the forecast period: Pharmacyclics'/Janssen's Imbruvica, which was approved for relapsed/refractory MCL patients in November 2013, Gilead's Zydelig, which was approved for relapsed/refractory FL patients in July 2014, and Roche's Gazyva, which will launch in 2015.

Highlights

Key Questions Answered

  • How will the launch of Imbruvica and Zydelig impact the treatment landscape of relapsed/refractory MCL and FL patients?
  • How will the launch of Gazyva and the subcutaneous formulation of MabThera help Roche protect their hematology franchise from biosimilar rituximab competition in the 5EU?
  • The new agents will launch first in one B-cell indication before seeking label expansion into broader NHL patient populations. How will companies expand their hematology candidates beyond their initial approvals?
  • Pharmacyclics has set a high pricing bar with a high ACOT for Imbruvica. How will this pricing strategy affect pricing of other pipeline agents, and will this be a barrier to entry in cost-conscious EU markets?
  • The new agents address significant unmet needs in the relapsed/refractory NHL population. What remaining opportunity will remain after their launch?

Key Findings

  • Imbruvica will gain significant patient share in the relapsed/refractory MCL market before expanding into the r/r FL setting. However, Zydelig's time-to-market advantage as well as potentially superior clinical profile in FL patients will result in Zydelig maintaining the market lead in these patients.
  • There is significant opportunity for the new agents Imbruvica and Zydelig, which are delivered orally and would greatly increase patient convenience in addition to providing superior clinical benefit over chemoimmunotherapy regimens.
  • Physicians in the US and 5EU are eager to eventually transition their patients onto chemo-free combination regimens, and the new oral agents in combination with Rituxan or Gazyva have the potential to address this need in the first line.
  • The loss of patent protection in 2013 for the gold-standard CD20 antibody MabThera (Rituxan) will have a significant impact on market growth in the 5EU, as biosimilar competition is expected beginning in 2018. By launching the second-generation CD20 antibody Gazyva, as well as a subcutaneous formulation of MabThera that greatly increases patient convenience, Roche will effectively maintain significant NHL patient share over biosimilar competitors in 2018.
  • Many relapsed/refractory NHL patients seek treatment in clinical trials, due to the low clinical efficacy conferred by available chemoimmunotherapy regimens after failure of first-line treatment. As the pipeline agents gain approval and enter the market, GlobalData anticipates that trial registration will decrease, contributing to overall market growth in the US and 5EU as more patients opt to receive treatment outside of the clinical trial setting.

Scope

  • Overview of B-cell NHL, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines for DLBCL, FL, MZL and MCL.
  • Annualized B-cell NHL (including DLBCL. FL. MZL and MCL) therapeutics market revenue, annual cost of therapy and patient share in the first-line and relapsed/refractory setting (as well as consolidation/maintenance for FL patients) forecast from 2013 to 2018.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the B-cell NHL therapeutics market
  • Pipeline analysis: The B-cell NHL pipeline is relatively small, but dominated by high profile novel therapies with the potential to be significant game changers.
  • Analysis of the current and future market competition in the global B-cell NHL markets, including insightful review of the key industry drivers, barriers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the B-cell NHL therapeutics markets in the US and 5EU.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NHL therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Forecast drug sales in the global B-cell NHL therapeutics market from 2013-2018.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Pathophysiology of Indolent and Aggressive B-Cell NHL
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
    • 4.1.1. Diagnostic Classification
  • 4.2. Treatment Overview

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global Trends
    • 5.3.1. US
    • 5.3.2. US
    • 5.3.3. 5EU
  • 5.4. Forecast Methodology
    • 5.4.1. Sources Used
    • 5.4.2. Forecast Assumptions and Methods
    • 5.4.3. Age-Standardized Incidence Rates
  • 5.5. Epidemiological Forecast for B-Cell NHL (2013-2023)
    • 5.5.1. Follicular Lymphoma
    • 5.5.2. Marginal Zone Lymphoma
    • 5.5.3. DLBCL
    • 5.5.4. Mantle Cell Lymphoma
  • 5.6. Discussion
    • 5.6.1. Epidemiological Forecast Insight
    • 5.6.2. Limitations of the Analysis
    • 5.6.3. Strengths of the Analysis

6. Current Treatment Options

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands, Follicular Lymphoma
    • 6.2.1. Imbruvica (ibrutinib)
    • 6.2.2. Revlimid (lenalidomide)
    • 6.2.3. Rituxan/MabThera (rituximab)
    • 6.2.4. Treanda (bendamustine)
    • 6.2.5. Velcade (bortezomib)
    • 6.2.6. Zevalin (ibritumomab tiuxetan)
    • 6.2.7. Zydelig (idelalisib, GS-1101, CAL-101)

7. Unmet Needs Assessment and Opportunity Analysis

  • 7.1. Overview
  • 7.2. Unmet Needs Analysis
    • 7.2.1. Unmet Need: Safe and Tolerable Front-Line Agents for Indolent NHL Patients that Prolong OS and Delay Relapse
    • 7.2.2. Unmet Need: Prolonged Survival Rates for Mantle Cell Patients
    • 7.2.3. Unmet Need: Improved Cure Rate for DLBCL Patients after Front-Line Therapy
    • 7.2.4. Unmet Need: Predictive and Prognostic Molecular Biomarkers
  • 7.3. Opportunity Analysis
    • 7.3.1. Opportunity: More Cost-Effective Therapies
    • 7.3.2. Opportunity: Better Consolidation/Maintenance Therapies for Follicular Patients
    • 7.3.3. Novel Agents for Front-Line DLBCL and Mantle Cell Lymphoma Therapy

8. R&D Strategies

  • 8.1. Overview
    • 8.1.1. Targeting Multiple NHL Subtypes and Lines of Therapy to Capture Greatest Patient Share
    • 8.1.2. Inhibiting New Targets in Relapsed/Refractory NHL Patients
    • 8.1.3. Developing Novel Drugs in Combination with Rituxan/MabThera to Replace Chemoimmunotherapy Regimens
    • 8.1.4. Franchise Management through Developing Novel Second-Generation Therapies to Replace Established Standards of Care at the End of Their Patent Life
    • 8.1.5. Small Biotechs Collaborating on Investigator-Sponsored Early-Stage Trials to De-Risk Later-Stage Studies
    • 8.1.6. Introducing New Routes of Drug Delivery to Improve Patient Convenience
  • 8.2. Clinical Trial Design
    • 8.2.1. Indolent B-Cell NHL
    • 8.2.2. Aggressive B-Cell NHL
    • 8.2.3. Clinical Endpoints
    • 8.2.4. Comparator Arms

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Promising Drugs in Clinical Development
    • 9.2.1. Arzerra (ofatumumab)
    • 9.2.2. Gazyva (obinutuzumab)
  • 9.3. Innovative Early-Stage Approaches
    • 9.3.1. Adcetris (brentuximab vedotin)
    • 9.3.2. Alisertib (MLN8237)
    • 9.3.3. Blinatumomab (AMG-101)
    • 9.3.4. Copanlisib (BAY 80-6946)
    • 9.3.5. Y-90 Epratuzumab
    • 9.3.6. Chimeric Antigen Receptor T-Cell Therapies

10. Pipeline Valuation Analysis

  • 10.1. Clinical Benchmark of Key Pipeline Drugs
  • 10.2. Commercial Benchmark of Key Pipeline Drugs
  • 10.3. Competitive Assessment
  • 10.4. Top Line Five Year Forecast
    • 10.4.1. US
    • 10.4.2. 5EU

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed NHL patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline agents
  • 11.5. Physicians and Specialists Included in This Study
  • 11.6. Survey of Prescribing Physicians
  • 11.7. About the Authors
    • 11.7.1. Authors
    • 11.7.2. Epidemiologist
    • 11.7.3. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Non-Hodgkin's Lymphomas
  • Table 2: Symptoms of Non-Hodgkin's Lymphoma
  • Table 3: The Ann Arbor Staging Criteria for NHL (Cotswolds Modification)
  • Table 4: Molecular Characteristics of Non-Hodgkin's Lymphoma (2008 WHO Classification)
  • Table 5: Treatment Guidelines for Non-Hodgkin's Lymphoma
  • Table 6: Risk Factors and Comorbidities for NHL
  • Table 7: US, Age- and Sex-Specific Incidence of B-Cell NHL during 2001-2010
  • Table 8: 6MM, Sources of B-Cell NHL Incidence Data
  • Table 9: 6MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 10: 6MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N (Row %), 2013
  • Table 11: 6MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N (Row %), 2013
  • Table 12: 6MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 13: 6MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N (Row %), 2013
  • Table 14: 6MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N (Row %), 2013
  • Table 15: 6MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 16: 6MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N (Row %), 2013
  • Table 17: 6MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N (Row %), 2013
  • Table 18: 6MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 19: 6MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N (Row %), 2013
  • Table 20: 6MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N (Row %), 2013
  • Table 21: Leading Treatments for NHL
  • Table 22: Product Profile - Imbruvica (ibrutinib)
  • Table 23: Imbruvica SWOT Analysis, 2013
  • Table 24: Product Profile - Revlimid (lenalidomide)
  • Table 25: Revlimid SWOT Analysis, 2013
  • Table 26: Product Profile - Rituxan (rituximab)
  • Table 27: Rituxan SWOT Analysis, 2013
  • Table 28: Product Profile - Treanda (bendamustine)
  • Table 29: Treanda SWOT Analysis, 2013
  • Table 30: Product Profile - Velcade (bortezomib)
  • Table 31: Velcade SWOT Analysis, 2013
  • Table 32: Product Profile - Zevalin (ibritumomab tiuxetan)
  • Table 33: Zevalin SWOT Analysis, 2013
  • Table 34: Product Profile - Zydelig (idelalisib)
  • Table 35: Zydelig SWOT Analysis, 2013
  • Table 36: Overall Unmet Needs - Current Level of Attainment
  • Table 37: Design of Current Registrational Trials in indolent NHL
  • Table 38: Design of Current Registrational Trials in Aggressive NHL
  • Table 39: Non-Hodgkin's Lymphoma - Phase III Pipeline, 2013
  • Table 40: Product Profile - Arzerra (ofatumumab)
  • Table 41: Arzerra SWOT Analysis, 2013
  • Table 42: Product Profile - Gazyva (obinutuzumab)
  • Table 43: Gazyva SWOT Analysis, 2013
  • Table 44: Early-Stage Pipeline Products in Non-Hodgkin's Lymphoma
  • Table 45: Clinical Benchmark of Key Marketed and Pipeline Drugs - Indolent NHL, Relapsed/Refractory Therapies
  • Table 46: Clinical Benchmark of Key Marketed and Pipeline Drugs - Aggressive NHL, Relapsed/Refractory Therapies
  • Table 47: Commercial Benchmark of Key Marketed and Pipeline Drugs
  • Table 48: Top Line Sales Forecasts ($bn) for NHL, 2013-2018
  • Table 49: Key Events Impacting Sales for NHL in the US and 5EU, 2013
  • Table 50: NHL Market in the US and 5EU - Drivers and Barriers, 2013
  • Table 51: Key Branded Drug Launch Dates
  • Table 52: Key Patent/Exclusivity Expiries
  • Table 53: Physicians Surveyed by Country

List of Figures

  • Figure 1: 6MM, Incident Cases of Follicular Lymphoma, Ages ≥30 Years, Both Sexes, N, 2013-2023
  • Figure 2: 6MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N, 2013
  • Figure 3: 6MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ≥30 Years, N, 2013
  • Figure 4: 6MM, Age-Standardized Incidence of Follicular Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, 2013
  • Figure 5: 6MM, Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, Both Sexes, N, 2013-2023
  • Figure 6: 6MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N, 2013
  • Figure 7: 6MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ≥30 Years, N, 2013
  • Figure 8: 6MM, Age-Standardized Incidence of Marginal Zone Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, 2013
  • Figure 9: 6MM, Incident Cases of DLBCL, Ages ≥30 Years, Both Sexes, N, 2013-2023
  • Figure 10: 6MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N, 2013
  • Figure 11: 6MM, Sex-Specific Incident Cases of DLBCL, Ages ≥30 Years, N, 2013
  • Figure 12:6MM, Age-Standardized Incidence of DLBCL (Cases per 100,000 Population), Ages ≥30 Years, 2013
  • Figure 13:6MM, Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, Both Sexes, N, 2013-2023
  • Figure 14: 6MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N, 2013
  • Figure 15: 6MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ≥30 Years, N, 2013
  • Figure 16:6MM, Age-Standardized Incidence of Mantle Cell Lymphoma (Cases per 100,000 Population), Ages ≥30 Years, 2013
  • Figure 17: Imbruvica - Phase II and III Trials in Indolent and Aggressive NHL
  • Figure 18: Revlimid - Phase II and III Trials in Indolent and Aggressive NHL
  • Figure 19: Velcade - Phase II and III Trials in Indolent and Aggressive NHL
  • Figure 20: Zevalin - Phase II and III Trials in Indolent and Aggressive NHL
  • Figure 21: Zydelig - Phase II and III Trials
  • Figure 22: Arzerra - Phase II and III Trials in Indolent and Aggressive NHL
  • Figure 23: Gazyva - Phase II and III Trials in Indolent and Aggressive NHL
  • Figure 24:Competitive Assessment of Key Marketed and Pipeline Drugs - Indolent NHL, Relapsed/Refractory Therapies, 2013-2018
  • Figure 25:Competitive Assessment of Key Marketed and Pipeline Drugs - Aggressive NHL, Relapsed/Refractory Therapies, 2013-2018
Back to Top